Global anthrax treatment market is projected to register a CAGR of 6.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Global Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country(U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the anthrax treatment market are:
Rising prevalence of anthrax infections
Increasing research funding and the development of novel therapies for anthrax treatment
Market Players:
The key market players for global anthrax treatment market are listed below:
Alembic Pharmaceuticals
Integrated Bio Therapeutics Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
EMERGENT
Sanofi
Elusys Therapeutics
Porton Biopharma
Lupin, Soligenix
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
ARISTO Pharmaceuticals Private Limited
INDOCO REMEDIES LTD.
Paratek Pharmaceuticals, Inc.
DEINOVE
BlueWillow Biologics.
GC Biopharma, corp.
Altimmune
TABLE OF CONTENTS
1 INTRODUCTION 75
- 1.1 OBJECTIVES OF THE STUDY 75
- 1.2 MARKET DEFINITION 75
- 1.3 OVERVIEW OF THE GLOBAL ANTHRAX TREATMENT MARKET 75
- 1.4 LIMITATIONS 77
- 1.5 MARKETS COVERED 77
2 MARKET SEGMENTATION 80
- 2.1 MARKETS COVERED 80
- 2.2 GEOGRAPHICAL SCOPE 81
- 2.3 YEARS CONSIDERED FOR THE STUDY 82
- 2.4 CURRENCY AND PRICING 82
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 83
- 2.6 MULTIVARIATE MODELLING 86
- 2.7 PRODUCT SEGMENT LIFELINE CURVE 86
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
- 2.9 DBMR MARKET POSITION GRID 88
- 2.10 MARKET APPLICATION COVERAGE GRID 89
- 2.11 VENDOR SHARE ANALYSIS 90
- 2.12 SECONDARY SOURCES 91
- 2.13 ASSUMPTIONS 91
3 EXECUTIVE SUMMARY 92
4 PREMIUM INSIGHTS 96
- 4.1 PESTEL ANALYSIS 98
- 4.2 PORTER'S FIVE FORCES 99
- 4.3 DEMOGRAPHIC TRENDS- 100
- 4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 102
- 4.4.1 INCIDENCE 102
- 4.4.2 DEVELOPED COUNTRIES- 102
- 4.4.3 DEVELOPING COUNTRIES- 102
- 4.5 PATIENT ENROLMENT STRATEGIES- 104
- 4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 108
- 4.7 CURRENT STATE OF ANTHRAX VACCINES 110
- 4.8 GLOBAL ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 114
- 4.9 GLOBAL ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 115
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR'S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY'S PIPELINE FOR ANTHRAX TREATMENT. 119
6 GLOBAL ANTHRAX TREATMENT MARKET: REGULATIONS 121
7 MARKET OVERVIEW 125
- 7.1 DRIVERS 127
- 7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 127
- 7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 127
- 7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 128
- 7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 128
- 7.2 RESTRAINTS 129
- 7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 129
- 7.2.2 FALSE DATA INTERPRETATION 130
- 7.3 OPPORTUNITIES 130
- 7.3.1 RISING PRODUCT LAUNCHES 130
- 7.3.2 RISING GOVERNMENT INITIATIVES 131
- 7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 131
- 7.4 CHALLENGES 132
- 7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 132
- 7.4.2 LACK OF SKILLED PROFESSIONALS 132
8 GLOBAL ANTHRAX TREATMENT MARKET, BY TYPE 134
- 8.1 OVERVIEW 135
- 8.2 CUTANEOUS ANTHRAX 138
- 8.2.1 ANTIBIOTICS 139
- 8.2.1.1 BY DRUGS 139
- 8.2.1.1.1 CIPROFLOXACIN 140
- 8.2.1.1.2 LEVOFLOXACIN 140
- 8.2.1.1.3 DOXYCYCLINE 140
- 8.2.1.1.4 AMPICILLIN 140
- 8.2.1.1.5 OTHERS 140
- 8.2.1.2 BY PRODUCT TYPES 140
- 8.2.1.2.1 GENERICS 140
- 8.2.1.2.2 BRANDED 140
- 8.2.1.2.2.1 CIPRO 141
- 8.2.1.2.2.2 LEVO 141
- 8.2.1.2.2.3 DOXY 141
- 8.2.1.2.2.4 AMPICI 141
- 8.2.1.2.2.5 OTHERS 141
- 8.2.2 ANTITOXINS 142
- 8.2.2.1 RAXIBACUMAB 142
- 8.2.2.2 OBILTOXAXIMAB (ANTHIM) 142
- 8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 142
- 8.2.2.4 OTHERS 142
- 8.2.3 VACCINES 143
- 8.2.4 SURGERY 143
- 8.3 PULMONARY ANTHRAX 143
- 8.3.1 ANTIBIOTICS 144
- 8.3.1.1 BY DRUGS 145
- 8.3.1.1.1 CIPROFLOXACIN 145
- 8.3.1.1.2 LEVOFLOXACIN 145
- 8.3.1.1.3 DOXYCYCLINE 145
- 8.3.1.1.4 AMPICILLIN 145
- 8.3.1.1.5 OTHERS 145
- 8.3.1.2 BY PRODUCT TYPES 146
- 8.3.1.2.1 GENERICS 146
- 8.3.1.2.2 BRANDED 146
- 8.3.1.2.2.1 CIPRO 146
- 8.3.1.2.2.2 LEVO 147
- 8.3.1.2.2.3 DOXY 147
- 8.3.1.2.2.4 AMPICI 147
- 8.3.1.2.2.5 OTHERS 147
- 8.3.2 ANTITOXINS 147
- 8.3.2.1 RAXIBACUMAB 147
- 8.3.2.2 OBILTOXAXIMAB (ANTHIM) 147
- 8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 147
- 8.3.2.4 OTHERS 148
- 8.3.3 VACCINES 148
- 8.3.3.1 RAXIBACUMAB 148
- 8.3.3.2 SURGERY 148
- 8.4 INTESTINAL ANTHRAX 148
- 8.4.1 ANTIBIOTICS 150
- 8.4.1.1 BY DRUGS 150
- 8.4.1.1.1 CIPROFLOXACIN 150
- 8.4.1.1.2 LEVOFLOXACIN 150
- 8.4.1.1.3 DOXYCYCLINE 150
- 8.4.1.1.4 AMPICILLIN 151
- 8.4.1.1.5 OTHERS 151
- 8.4.1.2 BY PRODUCT TYPES 151
- 8.4.1.2.1 GENERICS 151
- 8.4.1.2.2 BRANDED 151
- 8.4.1.2.2.1 CIPRO 152
- 8.4.1.2.2.2 LEVO 152
- 8.4.1.2.2.3 DOXY 152
- 8.4.1.2.2.4 AMPICI 152
- 8.4.1.2.2.5 OTHERS 152
- 8.4.2 ANTITOXINS 153
- 8.4.2.1 RAXIBACUMAB 153
- 8.4.2.2 OBILTOXAXIMAB (ANTHIM) 153
- 8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 153
- 8.4.2.4 OTHERS 153
- 8.4.3 VACCINES 154
- 8.4.3.1 RAXIBACUMAB 154
- 8.4.3.2 SURGERY 154
9 GLOBAL ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 155
- 9.1 OVERVIEW 156
- 9.2 PARENTERAL 159
- 9.3 ORAL 159
- 9.4 OTHERS 160
10 GLOBAL ANTHRAX TREATMENT MARKET, BY END USER 161
- 10.1 OVERVIEW 162
- 10.2 GOVERNMENT ORGANIZATION 165
- 10.3 HOSPITALS 165
- 10.4 ACADEMIC AND RESEARCH 166
- 10.5 OTHERS 168
11 GLOBAL VIRTUAL REALITY MARKET, BY GEOGRAPHY 169
- 11.1 GLOBAL 170
- 11.2 NORTH AMERICA 175
- 11.2.1 U.S. 192
- 11.2.2 CANADA 202
- 11.2.3 MEXICO 212
- 11.3 MIDDLE EAST AND AFRICA 222
- 11.3.1 SOUTH AFRICA 239
- 11.3.2 SAUDI ARABIA 248
- 11.3.3 UAE 257
- 11.3.4 EGYPT 266
- 11.3.5 ISRAEL 275
- 11.3.6 REST OF MIDDLE EAST AND AFRICA 284
- 11.4 EUROPE 285
- 11.4.1 GERMANY 301
- 11.4.2 FRANCE 312
- 11.4.3 U.K. 322
- 11.4.4 ITALY 333
- 11.4.5 RUSSIA 344
- 11.4.6 SPAIN 354
- 11.4.7 TURKEY 364
- 11.4.8 NETHERLANDS 374
- 11.4.9 SWITZERLAND 385
- 11.4.10 BELGIUM 396
- 11.4.11 REST OF EUROPE 407
- 11.5 ASIA-PACIFIC 408
- 11.5.1 CHINA 424
- 11.5.2 JAPAN 435
- 11.5.3 SOUTH KOREA 446
- 11.5.4 INDIA 457
- 11.5.5 AUSTRALIA 468
- 11.5.6 SINGAPORE 479
- 11.5.7 THAILAND 490
- 11.5.8 MALAYSIA 501
- 11.5.9 INDONESIA 512
- 11.5.10 PHILIPPINES 522
- 11.5.11 REST OF ASIA-PACIFIC 533
- 11.6 SOUTH AMERICA 534
- 11.6.1 BRAZIL 549
- 11.6.2 ARGENTINA 560
- 11.6.3 REST OF SOUTH AMERICA 571
12 GLOBAL ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 572
- 12.1 COMPANY SHARE ANALYSIS: GLOBAL 572
- 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 573
- 12.3 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 574
- 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 575
13 SWOT ANALYSIS 576
14 COMPANY PROFILE 577
- 14.1 BAYER AG 577
- 14.1.1 COMPANY SNAPSHOT 577
- 14.1.2 REVENUE ANALYSIS 577
- 14.1.3 COMPANY SHARE ANALYSIS 578
- 14.1.4 PRODUCT PORTFOLIO 578
- 14.1.5 RECENT DEVELOPMENTS 578
- 14.2 PFIZER INC. 579
- 14.2.1 COMPANY SNAPSHOT 579
- 14.2.2 REVENUE ANALYSIS 579
- 14.2.3 COMPANY SHARE ANALYSIS 580
- 14.2.4 PRODUCT PORTFOLIO 580
- 14.2.5 RECENT DEVELOPMENTS 580
- 14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 581
- 14.3.1 COMPANY SNAPSHOT 581
- 14.3.2 REVENUE ANALYSIS 581
- 14.3.3 COMPANY SHARE ANALYSIS 582
- 14.3.4 PRODUCT PORTFOLIO 582
- 14.3.5 RECENT DEVELOPMENT 582
- 14.4 SANOFI 583
- 14.4.1 COMPANY SNAPSHOT 583
- 14.4.2 REVENUE ANALYSIS 583
- 14.4.3 COMPANY SHARE ANALYSIS 584
- 14.4.4 PRODUCT PORTFOLIO 584
- 14.4.5 RECENT DEVELOPMENTS 584
- 14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 585
- 14.5.1 COMPANY SNAPSHOT 585
- 14.5.2 REVENUE ANALYSIS 585
- 14.5.3 PRODUCT PORTFOLIO 586
- 14.5.4 RECENT DEVELOPMENT 586
- 14.6 ALEMBIC PHARMACEUTICALS LIMITED 587
- 14.6.1 COMPANY SNAPSHOT 587
- 14.6.2 PRODUCT PORTFOLIO 587
- 14.6.3 RECENT DEVELOPMENTS 587
- 14.7 ALTIMMUNE 588
- 14.7.1 COMPANY SNAPSHOT 588
- 14.7.2 REVENUE ANALYSIS 588
- 14.7.3 PRODUCT PORTFOLIO 589
- 14.7.4 RECENT DEVELOPMENTS 589
- 14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 590
- 14.8.1 COMPANY SNAPSHOT 590
- 14.8.2 PRODUCT PORTFOLIO 590
- 14.8.3 RECENT DEVELOPMENTS 590
- 14.9 BLUEWILLOW BIOLOGICS. 591
- 14.9.1 COMPANY SNAPSHOT 591
- 14.9.2 PRODUCT PORTFOLIO 591
- 14.9.3 RECENT DEVELOPMENTS 591
- 14.10 DEINOVE 592
- 14.10.1 COMPANY SNAPSHOT 592
- 14.10.2 REVENUE ANALYSIS 592
- 14.10.3 PRODUCT PORTFOLIO 593
- 14.10.4 RECENT DEVELOPMENTS 593
- 14.11 EMERGENT 594
- 14.11.1 COMPANY SNAPSHOT 594
- 14.11.2 REVENUE ANALYSIS 594
- 14.11.3 PRODUCT PORTFOLIO 595
- 14.11.4 RECENT DEVELOPMENTS 595
- 14.12 ELUSYS THERAPEUTICS INC. 596
- 14.12.1 COMPANY SNAPSHOT 596
- 14.12.2 PRODUCT PORTFOLIO 596
- 14.12.3 RECENT DEVELOPMENTS 596
- 14.13 GC BIOPHARMA CORP. 597
- 14.13.1 COMPANY SNAPSHOT 597
- 14.13.2 REVENUE ANALYSIS 597
- 14.13.3 PRODUCT PORTFOLIO 598
- 14.13.4 RECENT DEVELOPMENTS 598